Do analysts recommend GOVX or LSTA?

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 23,134.20%. Given GeoVax Labs' higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is GOVX or LSTA more profitable?

Lisata Therapeutics' return on equity of -116.08% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Lisata Therapeutics N/A -116.08% -90.55%

Is GOVX or IMNN more profitable?

Imunon's return on equity of -358.01% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Imunon N/A -358.01% -132.91%

Does the media prefer GOVX or IMNN?

In the previous week, Imunon had 8 more articles in the media than GeoVax Labs. MarketBeat recorded 9 mentions for Imunon and 1 mentions for GeoVax Labs. Imunon's average media sentiment score of 0.55 beat GeoVax Labs' score of 0.00 indicating that Imunon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Imunon 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IMRN or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 23,134.20%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, IMRN or GOVX?

Immuron has higher revenue and earnings than GeoVax Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.91 -$3.38M N/A N/A GeoVax Labs $2.49M 0.90 -$21.47M -$11.34 N/A

Is IMRN or GOVX more profitable?

Immuron's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A GeoVax Labs N/A -743.64% -394.74%

Does the media refer more to IMRN or GOVX?

In the previous week, Immuron had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 2 mentions for Immuron and 1 mentions for GeoVax Labs. Immuron's average media sentiment score of 0.22 beat GeoVax Labs' score of 0.00 indicating that Immuron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, AKTX or GOVX?

Akari Therapeutics has higher earnings, but lower revenue than GeoVax Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A GeoVax Labs $2.49M 0.90 -$21.47M -$11.34 N/A

Is AKTX or GOVX more profitable?

Akari Therapeutics' return on equity of -147.45% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -147.45% -74.70% GeoVax Labs N/A -743.64% -394.74%

Does the media favor AKTX or GOVX?

In the previous week, Akari Therapeutics had 2 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for Akari Therapeutics and 1 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.00 beat Akari Therapeutics' score of -0.81 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Negative GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GOVX or APRE?

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 0.41 beat GeoVax Labs' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GeoVax Labs (GOVX) Competitors

$0.65 +0.04 (+7.24%)

As of 08/21/2026 04:00 PM Eastern

Compare

GOVX vs. LSTA, IMNN, IMRN, AKTX, and APRE

Should you buy GeoVax Labs stock or one of its competitors? GeoVax Labs's main competitors and comparable companies include Lisata Therapeutics (LSTA), Imunon (IMNN), Immuron (IMRN), Akari Therapeutics (AKTX), and Aprea Therapeutics (APRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GeoVax Labs compare to Lisata Therapeutics?

GeoVax Labs (NASDAQ:GOVX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Lisata Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Lisata Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.90	-$21.47M	-$11.34	N/A
Lisata Therapeutics	$100K	139.67	-$16.59M	-$1.64	N/A

Lisata Therapeutics' return on equity of -116.08% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Lisata Therapeutics	N/A	-116.08%	-90.55%

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GeoVax Labs has a beta of 3.73, meaning that its share price is 273% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 23,134.20%. Given GeoVax Labs' higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, GeoVax Labs had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for Lisata Therapeutics. GeoVax Labs' average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.

Company	Overall Sentiment
GeoVax Labs	Neutral
Lisata Therapeutics	Neutral

Summary

Lisata Therapeutics beats GeoVax Labs on 8 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to Imunon?

GeoVax Labs (NASDAQ:GOVX) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

GeoVax Labs has a beta of 3.73, suggesting that its share price is 273% more volatile than the broader market. Comparatively, Imunon has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market.

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 23,134.20%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 509.76%. Given GeoVax Labs' higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Imunon's return on equity of -358.01% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Imunon	N/A	-358.01%	-132.91%

In the previous week, Imunon had 8 more articles in the media than GeoVax Labs. MarketBeat recorded 9 mentions for Imunon and 1 mentions for GeoVax Labs. Imunon's average media sentiment score of 0.55 beat GeoVax Labs' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Imunon	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Imunon has lower revenue, but higher earnings than GeoVax Labs. Imunon is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.90	-$21.47M	-$11.34	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Summary

Imunon beats GeoVax Labs on 9 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to Immuron?

Immuron (NASDAQ:IMRN) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Immuron's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
GeoVax Labs	N/A	-743.64%	-394.74%

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 23,134.20%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

0.1% of Immuron shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immuron has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.73, meaning that its share price is 273% more volatile than the broader market.

Immuron has higher revenue and earnings than GeoVax Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.91	-$3.38M	N/A	N/A
GeoVax Labs	$2.49M	0.90	-$21.47M	-$11.34	N/A

In the previous week, Immuron had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 2 mentions for Immuron and 1 mentions for GeoVax Labs. Immuron's average media sentiment score of 0.22 beat GeoVax Labs' score of 0.00 indicating that Immuron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immuron beats GeoVax Labs on 8 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Akari Therapeutics' return on equity of -147.45% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
GeoVax Labs	N/A	-743.64%	-394.74%

In the previous week, Akari Therapeutics had 2 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for Akari Therapeutics and 1 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.00 beat Akari Therapeutics' score of -0.81 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Negative
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akari Therapeutics currently has a consensus price target of $32.33, suggesting a potential upside of 311.89%. GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 23,134.20%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Akari Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.73, suggesting that its stock price is 273% more volatile than the broader market.

Akari Therapeutics has higher earnings, but lower revenue than GeoVax Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
GeoVax Labs	$2.49M	0.90	-$21.47M	-$11.34	N/A

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Akari Therapeutics beats GeoVax Labs on 7 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to Aprea Therapeutics?

GeoVax Labs (NASDAQ:GOVX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 0.41 beat GeoVax Labs' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aprea Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Aprea Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.90	-$21.47M	-$11.34	N/A
Aprea Therapeutics	$290K	27.80	-$12.60M	-$1.08	N/A

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 23,134.20%. Aprea Therapeutics has a consensus price target of $3.07, suggesting a potential upside of 378.94%. Given GeoVax Labs' higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

GeoVax Labs has a beta of 3.73, indicating that its share price is 273% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

GeoVax Labs has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Summary

Aprea Therapeutics beats GeoVax Labs on 10 of the 15 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09M	$3.95B	$7.28B	$12.77B
Dividend Yield	N/A	3.64%	2.54%	11.08%
P/E Ratio	-0.06	11.58	271.51	24.24
Price / Sales	0.90	1,402.77	690.18	129.13
Price / Cash	N/A	103.29	76.89	53.23
Price / Book	1.27	17.90	13.45	6.38
Net Income	-$21.47M	-$12.50M	$3.47B	$348.30M
7 Day Performance	-10.08%	3.27%	2.12%	0.07%
1 Month Performance	-31.03%	7.76%	6.14%	2.89%
1 Year Performance	-96.65%	55.20%	24.99%	17.22%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	2.1265 of 5 stars	$0.65 +7.2%	$150.00 +23,134.2%	-96.6%	$2.09M	$2.49M	N/A	10	News Coverage Gap Up
LSTA Lisata Therapeutics	0.8114 of 5 stars	$1.08 -0.9%	$15.00 +1,288.9%	-37.2%	$9.82M	$170K	N/A	30
IMNN Imunon	2.6726 of 5 stars	$1.60 -3.0%	$10.00 +525.0%	-75.0%	$9.26M	N/A	N/A	30	Analyst Revision
IMRN Immuron	0.7186 of 5 stars	$1.08 -1.8%	N/A	-39.8%	$8.88M	$4.72M	N/A	N/A	News Coverage Upcoming Earnings Gap Up
AKTX Akari Therapeutics	2.2024 of 5 stars	$7.52 -0.3%	$32.33 +330.0%	-78.8%	$8.63M	N/A	N/A	9	News Coverage Analyst Upgrade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. LSTA, IMNN, IMRN, AKTX, and APRE

How does GeoVax Labs compare to Lisata Therapeutics?

Summary

How does GeoVax Labs compare to Imunon?

Summary

How does GeoVax Labs compare to Immuron?

Summary

How does GeoVax Labs compare to Akari Therapeutics?

Summary

How does GeoVax Labs compare to Aprea Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. LSTA, IMNN, IMRN, AKTX, and APRE

How does GeoVax Labs compare to Lisata Therapeutics?

Which has higher valuation & earnings, GOVX or LSTA?

Is GOVX or LSTA more profitable?

Do insiders & institutionals hold more shares of GOVX or LSTA?

Which has more risk & volatility, GOVX or LSTA?

Do analysts recommend GOVX or LSTA?

Does the media refer more to GOVX or LSTA?

Summary

How does GeoVax Labs compare to Imunon?

Which has more risk and volatility, GOVX or IMNN?

Do analysts recommend GOVX or IMNN?

Do insiders and institutionals have more ownership in GOVX or IMNN?

Is GOVX or IMNN more profitable?

Does the media prefer GOVX or IMNN?

Which has higher earnings and valuation, GOVX or IMNN?

Summary

How does GeoVax Labs compare to Immuron?

Is IMRN or GOVX more profitable?

Do analysts prefer IMRN or GOVX?

Do insiders and institutionals hold more shares of IMRN or GOVX?

Which has more risk and volatility, IMRN or GOVX?

Which has higher valuation & earnings, IMRN or GOVX?

Does the media refer more to IMRN or GOVX?

Summary

How does GeoVax Labs compare to Akari Therapeutics?

Is AKTX or GOVX more profitable?

Does the media favor AKTX or GOVX?

Do analysts rate AKTX or GOVX?

Which has more volatility & risk, AKTX or GOVX?

Which has higher earnings & valuation, AKTX or GOVX?

Do institutionals and insiders hold more shares of AKTX or GOVX?

Summary

How does GeoVax Labs compare to Aprea Therapeutics?

Does the media refer more to GOVX or APRE?

Do insiders & institutionals hold more shares of GOVX or APRE?

Which has better valuation & earnings, GOVX or APRE?

Do analysts prefer GOVX or APRE?

Which has more risk & volatility, GOVX or APRE?

Is GOVX or APRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools